We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
In the latest trading session, Gilead Sciences (GILD - Free Report) closed at $76.29, marking a +0.9% move from the previous day. This change outpaced the S&P 500's 0.44% loss on the day. Elsewhere, the Dow lost 0.53%, while the tech-heavy Nasdaq lost 0.26%.
Coming into today, shares of the HIV and hepatitis C drugmaker had lost 2.93% in the past month. In that same time, the Medical sector gained 5.37%, while the S&P 500 gained 3.59%.
Investors will be hoping for strength from GILD as it approaches its next earnings release, which is expected to be October 25, 2018. In that report, analysts expect GILD to post earnings of $1.62 per share. This would mark a year-over-year decline of 28.63%. Meanwhile, our latest consensus estimate is calling for revenue of $5.38 billion, down 17.31% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.57 per share and revenue of $21.58 billion, which would represent changes of -25.68% and -17.32%, respectively, from the prior year.
Any recent changes to analyst estimates for GILD should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. GILD is currently a Zacks Rank #1 (Strong Buy).
Investors should also note GILD's current valuation metrics, including its Forward P/E ratio of 11.51. This represents a discount compared to its industry's average Forward P/E of 29.49.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 97, putting it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
In the latest trading session, Gilead Sciences (GILD - Free Report) closed at $76.29, marking a +0.9% move from the previous day. This change outpaced the S&P 500's 0.44% loss on the day. Elsewhere, the Dow lost 0.53%, while the tech-heavy Nasdaq lost 0.26%.
Coming into today, shares of the HIV and hepatitis C drugmaker had lost 2.93% in the past month. In that same time, the Medical sector gained 5.37%, while the S&P 500 gained 3.59%.
Investors will be hoping for strength from GILD as it approaches its next earnings release, which is expected to be October 25, 2018. In that report, analysts expect GILD to post earnings of $1.62 per share. This would mark a year-over-year decline of 28.63%. Meanwhile, our latest consensus estimate is calling for revenue of $5.38 billion, down 17.31% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.57 per share and revenue of $21.58 billion, which would represent changes of -25.68% and -17.32%, respectively, from the prior year.
Any recent changes to analyst estimates for GILD should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. GILD is currently a Zacks Rank #1 (Strong Buy).
Investors should also note GILD's current valuation metrics, including its Forward P/E ratio of 11.51. This represents a discount compared to its industry's average Forward P/E of 29.49.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 97, putting it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.